Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study

To the Editor: Verrucous venous malformation (VVM) is a rare, congenital vascular malformation. 1 Wang L. Gao T. Wang G. Verrucous hemangioma: a clinicopathological and immunohistochemical analysis of 74 cases. J Cutan Pathol. 2014; 41: 823-830 Crossref PubMed Scopus (23) Google Scholar The treatment for VVM is particularly difficult. 2 Singh J. Sharma P. Tandon S. et al. Multiple verrucous hemangiomas: a case report with new therapeutic insight. Indian Dermatol Online J. 2017; 8: 254-256 Crossref PubMed Google Scholar Couto et al 3 Couto J.A. Vivero M.P. Kozakewich H.P. et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation. Am J Hum Genet. 2015; 96: 480-486 Abstract Full Text Full Text PDF PubMed Scopus (79) Google Scholar found a somatic MAP3K3 mutation in patients with VVM. MAP3K3 is an upstream molecule of the mammalian target of rapamycin signaling pathway, and sirolimus is an inhibitor of the mammalian target of rapamycin. Comment on “Sirolimus for the treatment of verrucous venous malformation: A retrospective cohort study”: Are we missing the lymphatic malformation component?Journal of the American Academy of DermatologyVol. 88Issue 3PreviewTo the Editor: We read with interest the study by Zhang et al1 on a cohort of patients with verrucous venous malformation (VVM) who were treated with sirolimus. The authors concluded that sirolimus is a reliable, effective, and well-tolerated treatment regimen for VVM. However, we believe that the possibility of lymphatic malformation (LM) was overlooked in this study. Full-Text PDF